

Repurposed Drug for Clostridium Difficile Infection

Track Code: 2018-SELE-68251

Categories:

- Medical/Health
- Pharmaceuticals

Keywords:

- Antibiotic
- C. diff
- Drug Repurposing
- Pharmaceuticals
- Repurposed Drug
- Vancomycin-resistant Enterococci
- VRE

Researchers at Purdue University developed a repurposed drug as a potent inhibitor of Clostridium difficile. Clostridium difficile is the most common and costly healthcare-associated infection with an estimated half a million cases and approximately 29,000 deaths occurring annually in the United States. The rate of death associated with Clostridium difficile infection (CDI) is rising, and the infection is occurring in populations previously considered to be at low risk. Treatment with the standard of care falls short; after treatment, patients' intestines become colonized by vancomycin-resistant enterococci (VRE). The repurposed drug is capable of killing hypervirulent strains of C. diff, suppressing C. diff spore formation, preventing VRE colonization, and avoiding absorption from the intestine. The drug is approved for its original indication outside of the US for oral consumption and in the US for topical application.

Advantages:

- Kills Clostridium difficile
- Suppresses Clostridium difficile spore formation
- Reduces vancomycin-resistant enterococci colonization

Potential Applications:

- Treatment of Clostridium difficile infection

People:

- Seleem, Mohamed (Project leader)
- Abutaleb, Nader

Intellectual Property:

Application Date: October 6, 2020

Type: Utility-Gov. Funding

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Application Date: October 7, 2019

Type: Provisional-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Application Date: October 9, 2018

Type: Provisional-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization

The Convergence Center

101 Foundry Drive, Suite 2500

West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: otcip@prf.org